{"id":"W4410915155","doi":"10.1038/s41591-025-03746-z","title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; McGill University; Université du Québec; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Perioperative; Chemotherapy; Lung cancer; Population; Clinical endpoint; Internal medicine; Adverse effect; Surgery; Phases of clinical research; Urology; Gastroenterology; Cancer; Clinical trial; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001316995,0.001276741,0.001239941,0.0002159058,0.0001769909,0.0007366889,0.0005708141,0.0007310695,0.002263499],"category_scores_gemma":[0.0008086849,0.0003236277,0.001214719,0.0001717482,0.000494155,0.0007023069,0.0003065527,0.001928877,0.0004362325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006897292,"about_ca_system_score_gemma":0.0007360784,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006088736,"about_ca_topic_score_gemma":0.002249447,"domain_scores_codex":[0.9996881,0.000190576,0.00001147278,0.00003830469,0.00002666581,0.00004485097],"domain_scores_gemma":[0.999688,0.00007096329,0.00007594265,0.00003513742,0.0000168495,0.0001131541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8782281,0.01122565,0.002760548,0.00109175,0.001883899,0.0001390434,0.0001189481,0.002105894,0.008465011,0.00061245,0.004268238,0.08910048],"study_design_scores_gemma":[0.807734,0.1786549,0.005523184,0.00009063097,0.000940994,0.0001764414,0.00005137942,0.001437443,0.001829285,0.0004734159,0.00305684,0.00003149441],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890043,0.00659777,0.0004236931,0.0005689329,0.0003283173,0.0007052533,0.0005957099,0.00005845356,0.001717573],"genre_scores_gemma":[0.9874797,0.003736921,0.001208213,0.001135194,0.0003753385,0.001420156,0.001495834,0.00002204025,0.003126578],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002263499,"threshold_uncertainty_score":0.007572114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02275397738876778,"score_gpt":0.383386960480376,"score_spread":0.3606329830916082,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}